| Literature DB >> 36003208 |
Annalee Johnson-Kwochka1, Eduardo F Salgado1, Casey A Pederson2,3, Matthew C Aalsma2,3, Michelle P Salyers1.
Abstract
Justice-involved youth (JIY) have high rates of behavioral health disorders, but few can access, much less complete, treatment in the community. Behavioral health treatment completion among JIY is poorly understood, even within treatment studies. Measurement, reporting, and rates of treatment completion vary across studies. This systematic review and meta-analysis synthesizes the literature on rates of treatment completion among JIY enrolled in research studies and identifies potential moderators. After systematically searching 6 electronic databases, data from 13 studies of 20 individual treatment groups were abstracted and coded. A meta-analysis examined individual prevalence estimates of treatment completion in research studies as well as moderator analyses. Prevalence effect sizes revealed high rates of treatment completion (pr = 82.6). However, analysis suggests a high likelihood that publication bias affected the results. Treatment groups that utilized family- or group-based treatment (pr = 87.8) were associated with higher rates of treatment completion compared to treatment groups utilizing individual treatment (pr = 61.1). Findings suggest that it is possible to achieve high rates of treatment completion for JIY, particularly within the context of family- and group-based interventions. However, these findings are limited by concerns about reporting of treatment completion and publication bias.Entities:
Keywords: Adolescent; behavioral medicine; juvenile delinquency; meta-analysis; patient participation
Year: 2022 PMID: 36003208 PMCID: PMC9389282 DOI: 10.1017/cts.2022.418
Source DB: PubMed Journal: J Clin Transl Sci ISSN: 2059-8661
PRISMA reporting checklist for systematic reviews and meta-analysis
| Section/topic | # | Checklist item | Reported on page # |
|---|---|---|---|
| Title | |||
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both. | 1 |
| Abstract | |||
| Structured summary | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 2 |
| Introduction | |||
| Rationale | 3 | Describe the rationale for the review in the context of what is already known. | 3 - 6 |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | 5 - 6 |
| Methods | |||
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | NA |
| Eligibility criteria | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | 6 |
| Information sources | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | 7 |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | 7, Table |
| Study selection | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | 6–7 |
| Data collection process | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | 7 |
| Data items | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | 7 - 9 |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | 9 |
| Summary measures | 13 | State the principal summary measures (e.g., risk ratio, difference in means). | 9 |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I [ | 9–11 |
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). | 11 |
| Additional analyses | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. | 10 - 11 |
| Results | |||
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | 7, 11, Fig. |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. | 11–13, Table |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome-level assessment (see item 12). | 13 |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group and (b) effect estimates and confidence intervals, ideally with a forest plot. | 13, Fig. |
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency. | 13, Table |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see Item 15). | 14 |
| Additional analysis | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). | 13 |
| Discussion | |||
| Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). | 14- 15, 18 |
| Limitations | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). | 16 |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence and implications for future research. | 15–18 |
| Funding | |||
| Funding | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. | NA |
Database search terms
| Database | Search Terms |
|---|---|
| PSYCHInfo | ((MM “Substance Use Treatment” OR MM “Alcohol Treatment” OR MM “Mental Health Services” OR MM “Community Mental Health Services”) AND (MM “Juvenile Delinquency” OR MM “Juvenile Justice”) using PSYCHInfo subject headings thesaurus |
| CINAHL | ((MM “Substance Use Rehabilitation Programs+” OR MM “Mental Health Services+”) AND (MM “Juvenile Offenders+” OR MM “Juvenile Delinquency”)) using CINAHL subject headings |
| PubMed | ((“juvenile delinquency” [MeSH Terms]) AND ((“substance-related disorders“[MeSH Terms]) OR (“mental processes/psychology“[MeSH Terms])) AND (“treatment outcome“[MeSH Terms])) using MeSH terms |
| ClinicalTrials.gov | (“juvenile justice” OR “juvenile delinquent”) AND (“treatment” OR “intervention” OR “therapy”) | (“Mental health disorder” OR “substance use disorder”) |
| SCOPUS | ((“juvenile justice” OR “juvenile delinquent”) AND (“mental health treatment” OR “substance use treatment” OR “behavioral health treatment” OR “mental health intervention” OR “substance use intervention” OR “behavioral health intervention”)) |
| Web of Science | (ALL = (adolescent OR youth OR juvenile) AND ALL = (“juvenile justice” |
Fig. 1.PRISMA flow chart.
Effect size variables and demographics
| Effect Size Variables | Demographics | |||||||
|---|---|---|---|---|---|---|---|---|
| Eligible N | Initiation N | Treatment Group | Treatment | Completion N | Age (SD) | % Minority | % Female | |
| Borduin et al., 2009 | 51 | 48 | MST (T) | 24 | 24 | 14 (1.9) | 29.2 | 4.2 |
| SAU (C) | 24 | 22 | ||||||
| Burrow-Sanchez et al., 2015 | 71 | 70 | Standard CBT (T1) | 36 | 24 | 15.3 (1.3) | 100.0 | 11.1 |
| Accommodated CBT (T2) | 34 | 27 | 15.1 (1.2) | 100.0 | 8.8 | |||
| Dakof et al., 2015 | 119 | 112 | MDFT (T1) | 55 | 53 | 16.0 (1.1) | 100.0 | 10.9 |
| AGT (T2) | 57 | 49 | 16.1 (0.9) | 100.0 | 10.5 | |||
| Henderson et al., 2016 | 145 | 126 | ACRA (T) | 63 | 40 | 15.1 (1.1) | 25.2 | 20.6 |
| SAU
| 63 | not reported | 15.3 (1.0) | 22.0 | 26.9 | |||
| Henggeler et al., 1999 | 141 | 118 | MST (T) | 58 | 57 | 15.7 (1.0) | 53.0 | 21.1 |
| SAU (C) | 60 | 3 | ||||||
| Henggeler et al., 2015 | 115 | 104 | CM (T) | 73 | 63 | 15.4 (0.9) | 43.5 | 17.6 |
| SAU (C) | 42 | 41 | ||||||
| Kaminer et al., 2019 | 142 | 113 | MET-CBT (T) | NA | 102 | 16.1 (1.0) | 62.3 | 12.1 |
| Letourneau et al., 2009 | 178 | 131 | MST (T) | 68 | 62 | 14.6 (1.7) | 85.0 | 2.4 |
| SAU (C) | 66 | 58 | ||||||
| Schaeffer et al., 2014 | 104 | 97 | Community Restitution (T) | 50 | 33 | 15.8 (0.9) | 82.0 | 17.0 |
| SAU
| 47 | not reported | 15.9 (0.9) | 85.0 | 18.0 | |||
| Sharkey et al., 2010 | not reported | 150 | Neighborhood enrichment (T) | NA | 150 | 16.02 (1.2) | 80.9 | 38.0 |
| Silovsky et al., 2019 | 418 | 320 | CBT (T) | NA | 188 | 12.8 (1.6) | not reported | 9.1 |
| Tolou-Shams et al., 2017 | 233 | 60 | Family Affect Management(T1) | 30 | 25 | 15.6 (1.3) | 50.7 | 30.0 |
| Health Promotion (T2) | 30 | 22 | ||||||
| Walker et al., 2019 | 136 | 101 | Girls Active Learning | 66 | 57 | 15.2 (1.7) | 41.0 | 100.0 |
| SAU
| 35 | not reported | ||||||
Note: In some cases, authors reported demographics for all participants (rather than by treatment group) after finding that there were no significant demographic differences between treatment groups.
Abbreviations: Multisystemic Therapy (MST), Services as Usual (SAU), Cognitive Behavioral Therapy (CBT), Multidimensional Family Therapy (MDFT), Motivational Enhancement Therapy (MET), Adolescent Group Treatment (AGT), Adolescent Community Reinforcement Approach (ACRA), Contingency Management (CM).
SAU treatment groups that did not define or report treatment completion data were not included in analyses.
Methodological variables
| Methodological Variables | ||||||||
|---|---|---|---|---|---|---|---|---|
| Study Design | Intervention Focus | Justice-Involvement Type | Treatment Mandates | Type of Treatment | Engagement Interventions | Treatment Length | Completion Criteria | |
| Borduin et al., 2009 | RCT | Problematic Sexual Behavior | arrested; could be pre- or post- adjudication | Court-ordered outpatient sexual offender counseling | MST; family (T) | Services provided in convenient location; therapists available 24/7 | Averaged 30 weeks | Collaboratively identified by MST therapist and patient |
| SAU; individual (C) | None reported | Averaged 30 weeks | Collaboratively identified by MST therapist & patient | |||||
| Burrow-Sanchez et al., 2015 | RCT | Any SUD | heterogeneous; all participants referred by juvenile probation department | 74% court-ordered to treatment | Standard-CBT; group (T1) | None reported | 12 weeks | Attended 9 of 12 treatment sessions |
| accommodated CBT; family (T2) | Treatment manual modified to increase relevancy for Latino adolescents and include family treatment; promoted regular phone/mail contact between therapist and patients/families | 12 weeks | Attended 9 of 12 treatment sessions | |||||
| Dakof et al., 2015 | RCT | Any SUD | All participants enrolled in drug court | Court-ordered to treatment | MDFT; family (T1) | Financial assistance with transportation; services provided in convenient location; included family in treatment planning | Averaged 20 weeks | Graduation from drug court |
| Adolescent Group Treatment; group (T2) | Financial assistance with transportation; therapists reached out to DC and family if youth failed to attend | Averaged 20 weeks | Graduation from drug court | |||||
| Henderson et al., 2016 | RCT | Any SUD | On probation | Not reported | Adolescent-Community Reinforcement Approach; individual (T) | Financial assistance with transportation; services provided in convenient location | Averaged 36 weeks | Attended 3 or more sessions |
| SAU; individual
| None reported | Averaged 36 weeks | Not specified | |||||
| Henggeler et al., 1999 | RCT | Any SUD | Formal or informal probation | Not reported | MST; family (T) | Services provided in convenient location; therapists available 24/7 | Averaged 18 weeks | Collaboratively identified by MST therapist & patient |
| SAU; individual (C) | None reported | Not Described | Collaboratively identified by MST therapist & patient | |||||
| Henggeler et al., 2015 | RCT | Problematic drug use | All participants enrolled in drug court | Court-ordered to treatment | Contingency management – family engagement; family (T) | Contingency management intervention; included family in treatment planning | Averaged 20 weeks | Graduation from drug court |
| SAU; group (C) | None reported | Averaged 12 weeks | Graduation from drug court | |||||
| Kaminer et al., 2019 | Non-controlled | Cannabis use disorder | All participants referred by juvenile probation department | Not reported | MET-CBT; individual (T) | None reported | 7 weeks + additional 10 weeks for non-responders | Attending at least the first and last session of each phase |
| Letourneau et al., 2009 | RCT | Problematic sexual behavior | On probation or in a diversion program | Court-ordered outpatient sexual offender counseling | MST; family (T) | Services provided in convenient location; therapists available 24/7 | Averaged 28.4 weeks | Collaboratively identified by MST therapist & patient |
| SAU; group (C) | None reported | Averaged 50 weeks | Collaboratively identified by MST therapist & patient | |||||
| Schaeffer et al., 2014 | RCT | Any SUD | All participants referred by juvenile probation department | Not reported | Community restitution apprentice-focused training; individual (T) | Financial assistance with transportation; individualized program attendance schedules coordinated with schools | 6 months | Attendance for a minimum of 100 hrs of instruction & proficiency in all core skill areas |
| SAU; individual
| None reported | Not described | Not specified | |||||
| Sharkey et al., 2010 | Non-controlled | Any SUD | Identified for services through juvenile probation or truancy | Not reported | Neighborhood enrichment with vision involving services, treatment, and services; family | Services centrally located for easier transportation; culturally modified treatment by recruiting providers from community | Not described | Completion of curriculum |
| Silovsky et al., 2019 | Non-controlled | Problematic sexual behavior | Juvenile probation actively involved in all treatment teams; participants on probation or diverted | 42% court-ordered to treatment | CBT with concurrent groups for youth and caregivers; family (T) | None reported | Not described | Completion of curriculum |
| Tolou-Shams et al., 2017 | RCT | Problematic drug use | All participants enrolled in drug court | Not reported; notes that court was unaware of youth participation in study | Family-based Affect Management Intervention; family (T1) | None reported | 7 weeks | Completed core intervention (4 weeks) |
| Adolescent-only Health Promotion Intervention; individual (T2) | None reported | 7 weeks | Completed core intervention (4 weeks) | |||||
| Walker et al., 2019 | Quasi-experimental | Problematic drug use | On probation | Not reported | Girls Only Active Learning; group (T) | Weekly text messages to parents about attendance and the weekly program topic | 10 weeks | Completed if youth did not miss more than 3 sessions |
| SAU; individual
| None reported | Not described | Not specified | |||||
Abbreviations: Multisystemic Therapy (MST), Services as Usual (SAU), Cognitive Behavioral Therapy (CBT), Multidimensional Family Therapy (MDFT), Motivational Enhancement Therapy (MET).
In some studies, Services as Usual (SAU) conditions did not report treatment completion criteria or data. These conditions were not included in analyses.
Fig. 2.Treatment completion by treatment type. Note: Treatment groups are marked as T (treatment group), C (control group), or T1 and T2 for multiple treatments in comparative effectiveness studies.
Effect sizes and associated statistics
| Full model results for meta-analysis | ||||||||
|---|---|---|---|---|---|---|---|---|
| Number | Effect | 95% CI | Range |
| I2
| Begg’s rank correlation | Egger’s weighted | |
| Treatment | 20 | 82.6 | 70.6, 90.3 | 5.0–98.0 | 221.3 | 91.4 | 0.08 | < 0.01 |
| Mixed effects models for analysis of categorical moderators | ||||||||
|
| Effect | 95 % CI | Range |
|
|
| ||
|
| ||||||||
| SUD | 15 | 80.0 | 66.7, 96.9 | 1.6–99.7 | 0.63 | 1 | 0.39 | |
| Other | 5 | 88.7 | 66.7, 96.9 | 40.3–99.9 | ||||
|
| ||||||||
| Family or Group | 14 | 87.8 | 78.9, 93.2 | 38.0–99.9 | 4.31 | 1 | 0.04 | |
| Individual | 6 | 61.1 | 30.4, 84.9 | 1.6–97.9 | ||||
|
| ||||||||
| Absent | 9 | 75.9 | 49.7, 90.1 | 1.6–99.7 | 0.9 | 1 | 0.33 | |
| Present | 11 | 86.0 | 75.4, 92.5 | 50.0–99.9 | ||||
| Meta-regression models for analysis of continuous moderators | ||||||||
| Coefficient | Standard | 95% CI |
| |||||
| % Minority | 0.17 | 0.13 | –0.09, 0.42 | 0.21 | ||||
Fig. 3.Funnel plot of treatment completion with imputed studies. Note: Imputed studies are shown in black.